News

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with…

8 months ago

Nexstim Receives NBS System 6 Order from Hospital in United States

Press release, Helsinki, 20 November 2023 at 11 AM (EET) Nexstim Receives NBS System 6 Order from Hospital in United…

8 months ago

Connect, Collaborate, Innovate: the PSCC Unveils ‘PSCC Connect’, the Association of Economic Stakeholders in Oncology

Press Release, November 20, 2023 Connect, Collaborate, Innovate: the PSCC Unveils 'PSCC Connect', the Association of Economic Stakeholders in Oncology…

8 months ago

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair…

8 months ago

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com Attachment…

8 months ago

Update on merger EC offered remedy proposal

Read the full announcement in PDF Attachment Update on merger EC offered remedy proposal

8 months ago

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2-…

8 months ago

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs…

8 months ago

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

  Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has…

8 months ago